Kobayashi Kazuki, Einama Takahiro, Tsunenari Takazumi, Yonamine Naoto, Takao Mikiya, Takihata Yasuhiro, Tsujimoto Hironori, Ueno Hideki, Tamura Katsumi, Ishida Jiro, Kishi Yoji
Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.
Department of Radiology, Tokorozawa PET Diagnostic Imaging Clinic, Tokorozawa, Saitama 359-1124, Japan.
Oncol Lett. 2024 Apr 23;27(6):279. doi: 10.3892/ol.2024.14412. eCollection 2024 Jun.
Tumor resectability, which is increasingly determined based on preoperative chemotherapy, is critical in determining the best treatment for pancreatic cancers. The present study evaluated the usefulness of serum carbohydrate antigen 19-9 (CA19-9) and the preoperative 8F-fluorodeoxyglucose positron emission tomography/computed tomography standardized uptake value (SUV) percentage change (SUVmax%=[(SUVmax2-SUVmax1)/SUVmax1] ×100, where SUVmax1 and SUVmax2 represent the initial and delayed phases, respectively) as biological factors indicative of tumor resectability. The present study included patients with resectable pancreatic cancer who underwent complete surgical resection, for whom both CA19-9 and SUVmax% were documented using cut-off values of 500 U/ml and 24.25%, respectively. Patients were classified as follows: i) High CA19-9 and SUVmax%: both CA19-9 and SUVmax% were elevated; ii) high CA19-9 or SUVmax%: either CA19-9 or SUVmax% were elevated; or iii) low CA19-9 and SUVmax%: neither value met the cut-off. Relapse-free survival (RFS) and overall survival (OS) were calculated, for which univariate and multivariate analyses were performed. Of the 86 patients included, 39 were classified as high CA19-9 or SUVmax% and 12 as high CA19-9 and SUVmax%, with the former group having a significantly worse RFS (vs. low CA19-9 and SUVmax%; P<0.001; vs. high CA19-9 or SUVmax%; P=0.011) and OS (vs. low CA19-9 and SUVmax%, P=0.002; vs. high CA19-9 or SUVmax%, P<0.001). Therefore, high CA19-9 and SUVmax% was an independent predictor of worse RFS (P<0.001) and OS (P=0.003). In conclusion, CA19-9 and SUVmax% can be utilized as biological indicators of resectability.
肿瘤可切除性越来越多地基于术前化疗来确定，这对于确定胰腺癌的最佳治疗方案至关重要。本研究评估了血清糖类抗原19-9（CA19-9）和术前8F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描标准化摄取值（SUV）百分比变化（SUVmax% = [（SUVmax2 - SUVmax1）/SUVmax1]×100，其中SUVmax1和SUVmax2分别代表初始期和延迟期）作为指示肿瘤可切除性的生物学因素的有用性。本研究纳入了接受完整手术切除的可切除胰腺癌患者，分别使用500 U/ml和24.25%的临界值记录了他们的CA19-9和SUVmax%。患者分为以下几类：i）高CA19-9和SUVmax%：CA19-9和SUVmax%均升高；ii）高CA19-9或SUVmax%：CA19-9或SUVmax%升高；或iii）低CA19-9和SUVmax%：两者均未达到临界值。计算无复发生存期（RFS）和总生存期（OS），并进行单因素和多因素分析。在纳入的86例患者中，39例被分类为高CA19-9或SUVmax%，12例为高CA19-9和SUVmax%，前一组的RFS（与低CA19-9和SUVmax%相比；P<0.001；与高CA19-9或SUVmax%相比；P = 0.011）和OS（与低CA19-9和SUVmax%相比，P = 0.002；与高CA19-9或SUVmax%相比，P<
